ScreenerHero

CRBPCorbus Pharmaceuticals Holdings, Inc.

NAS · US · Healthcare · Biotechnology · corbuspharma.com
10.38USD+3.90%Mkt Cap: 200.76M $P/E: —

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of N…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap200.76M $
Enterprise Value76.64M $
Revenue (TTM)—
Gross Profit-90.26M $
Net Income (TTM)-78.54M $
Revenue/Share—
Last Price10.38 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees36
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS21833P3010
Valuation
P/E (Trailing)—
P/E (Forward)-1.78
PEG—
EV/EBITDA-0.72
EV/Revenue—
P/S—
P/B1.80
EPS (TTM)-6.02
EPS (Forward)-5.51
52W Range
7.12024% of range20.56
52W High20.56 USD
52W Low7.120 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-53.24%
ROA-46.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.49M $
CapEx (TTM)7.00K $
FCF Margin—
FCF Yield-24.71%
Net Debt-113.68M $
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.01
Current Ratio5.71
Quick Ratio5.56
Book Value/Sh5.476 USD
Cash/Share6.098 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateFeb 14, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)34.52 USD
Upside (mean)+232.6%
Target Range17.25 USD – 48.00 USD
$17.25+232.6% to mean$48.00
# Analysts10
Ownership
Shares Out.19.34M
Float15.16M
Insiders1.20%
Institutions73.36%
Short Interest
Short Ratio7.4d
Short % Float14.17%
Short % Out.12.32%
Shares Short2.30M
Short (prev mo.)1.95M
Technical
SMA 509.087 (+14.2%)
SMA 2009.280 (+11.9%)
Beta2.62
S&P 52W Chg18.16%
Avg Vol (30d)321.75K
Avg Vol (10d)463.85K
Technical Indicators
RSI (14)61.9
MACD0.3289
MACD Signal0.2514
MACD Hist.+0.0775
BB Upper10.57 USD
BB Middle9.558 USD
BB Lower8.547 USD
BB Width21.14%
ATR (14)0.5250 USD
Vol Ratio (20d)1.73x